This is a useful newspaper article discussing persisting difficulties that occur for some after taking psychedelics and gives contact details for potential sources of help.

We outline the relevance of the ‘social cure’ model, supported by strong empirical evidence in social identity and health literature, emphasizing the importance of group contexts and social identity-based relationships in the theraputic effects of psychedelics.

This guide was put together in a collaborative effort with F.I.V.E. to inform and educate persons interested in 5-MeO-DMT about the pharmacology, drug interaction risks, potential for Serotonin Toxicity, and some risk management or stratification tools.

We aimed to create a standardized tool for recording clinically relevant side effects of psychedelics and MDMA, including their severity, duration, impact, and treatment-relatedness.

The Louisiana Addiction Research Center at LSU Health Shreveport have been awarded a five-year, $2.4 million research grant from the National Institute on Drug Abuse (NIDA) to uncover critical insights into how psychedelics could be used as a therapeutic to treat methamphetamine addiction.

The pharmacodynamic effects of lysergic acid diethylamide (LSD) are diverse and different in different individuals. Effects of other psychoactive substances have been shown to be critically influenced by non-pharmacological factors such as personality traits and mood states. The aim of this study was to determine pharmacological and psychological predictors of the LSD effects in healthy human subjects.

We aim to systematically review and meta-analyze the effectiveness and safety of psychedelics [psilocybin, ayahuasca (active component DMT), LSD and MDMA] in treating symptoms of various mental disorders.

MindBio's thesis is that microdosing psychedelic medicines is a globally scalable, effective, affordable way to treat patients and will not have the same cost and time burden on patients that clinic based hallucinogenic treatments present.

Of the available psychedelic treatments for depressive symptoms, patients treated with high dose psilocybin showed better responses than those treated with placebo in the antidepressant trials, but the effect size was small.

MAPS have just given a grant of $200K to see if MDMA can enhance the effectiveness of Massed Exposure Therapy (MET). MET delivers 10 x 90min exposure therapy sessions over 10 days and has been shown to be pretty much as effective to the one 90min session per week for 10 weeks of standard Prolonged Exposure Therapy. As MAPS comment "This study is one of the first trials exploring whether psychedelic-assisted therapy can enhance an existing evidence-based PTSD therapeutic treatment."

Ben Malcolm (aka the Spirit Pharmacist) produces some of the best material available on psychedelic drug interactions.

What is particularly surprising is the stark contrast between the FDA’s decision and the conclusions reached by the Dutch State Committee on MDMA. Based on the same body of evidence, the Dutch committee (consisting of scientists, psychiatrists, legal experts, drug prevention and harm reduction specialists) arrived at a radically different conclusion: MDMA-AT is promising, effective, relatively safe and warrants more scientific research to further explore its therapeutic potential.

Average pill strength has increased in 2024, back to pre-pandemic levels (>180mg MDMA); Total pill weight can be a simple indicator of high strength pills and flag up the need for extra caution.

I wanted to put together an article and video explaining my perspective on the FDA's recent decision of not approve MDMA-assisted therapy for the treatment of PTSD (at least at this time).

The results from six studies demonstrate a significant association between psychedelic use and lower levels of rumination, providing evidence that rumination may serve as a key cognitive factor in psychedelic treatment.

Contrary to clinical recommendations, only 10% and 22%, respectively, of survey respondents agreed that music for psychedelic experiences should be unfamiliar and without understandable lyrics. Furthermore, our data suggest potential unique benefits of psychedelic experiences devoid of music, particularly with the shortest and longest acting substances.

The notably strong association of brief scales with full versions combined with associations with therapeutic outcomes provide initial support for the MEQ-4 and CEQ-7. These findings, combined with substantial reductions in participant/patient burden, support the use of the MEQ-4 and CEQ-7 for a wide variety of research and patient treatment settings.

Balancing the need for effective treatments against the potential for serious adverse events in those undergoing psilocybin therapy with a family history of BD, we argue for caution in psychedelic clinical trials but not outright exclusion of these individuals. Our risk stratification tool allows for more nuanced inclusion and exclusion criteria.

Fairly heart-breakingly for many people suffering from PTSD and other disorders, the US Food & Drug Agency has turned down Lykos Therapeutics new drug application for MDMA.

We offer directions for future research in minimising the risk of false and potentially harmful beliefs arising from psychedelics. Ultimately, knowing how psychedelics may facilitate false insights and beliefs is crucial if we are to optimally leverage their therapeutic potential.